Yan Tao, Kang Guiqiong, Meng Yun, Zhang Liping, Jiang Qing, Shen Na, Li Huadong, Xu Meifang, Yu Lili, Ni Guangpu, Ma Haofeng, Guo Feng, Cui Yulei, Che Fengyuan
Department of Neurology, Postgraduate Training Base of Linyi People's Hospital, Guangzhou University of Chinese Medicine, Linyi 276000, Shandong Province, China; Department of Neurosurgery, Linyi People's Hospital, Linyi 276000, Shandong Province, China; Shandong Provincial Clinical Research Center for Geriatric Diseases, Linyi 276000, Shandong Province, China; Key Laboratory of Neurophysiology, Health Commission of Shandong, Linyi 276000, Shandong Province, China; Linyi Key Laboratory of Neurophysiology, Key Laboratory for Translational Oncology, Xuzhou Medical University, Linyi 276000, Shandong Province, China.
Department of Neurology, Postgraduate Training Base of Linyi People's Hospital, Guangzhou University of Chinese Medicine, Linyi 276000, Shandong Province, China; Shandong Provincial Clinical Research Center for Geriatric Diseases, Linyi 276000, Shandong Province, China; Key Laboratory of Neurophysiology, Health Commission of Shandong, Linyi 276000, Shandong Province, China; Linyi Key Laboratory of Neurophysiology, Key Laboratory for Translational Oncology, Xuzhou Medical University, Linyi 276000, Shandong Province, China.
Int Immunopharmacol. 2025 Jun 26;159:114945. doi: 10.1016/j.intimp.2025.114945. Epub 2025 May 27.
Intracerebral hemorrhage (ICH) is a severe cerebrovascular disorder with extremely high mortality and disability rates. Currently, effective medications for ICH are scarce, and the development of novel and efficacious drugs for its management is urgently needed. Neuronal ferroptosis and neuroinflammation are important pathophysiological processes occurring during the progression of ICH. Nevertheless, the potential relationship between neuronal ferroptosis and neuroinflammation during ICH remains to be clarified. Therefore, elucidating this relationship and further developing therapeutic drugs may provide feasible treatments for ICH. Here, we confirmed that ICH can induce neuronal ferroptosis, which can result in proinflammatory microglial polarization and ultimately trigger neuroinflammatory progression after ICH. Qinglongyi nanoparticle (QLY NP) treatment can suppress neuronal ferroptosis, thereby inhibiting proinflammatory microglial polarization, reducing the hematoma volume in mice and ultimately facilitating neuronal survival and alleviating neuroinflammation in the context of ICH. Concurrently, QLY NP treatment resulted in minimal toxicity in mice. Overall, we showed that the QLY NPs could inhibit neuronal ferroptosis, thereby alleviating neuroinflammation and ultimately leading to promising therapeutic outcomes in an ICH model. Hence, with further research, QLY NPs may be an efficacious treatment for ICH.
脑出血（ICH）是一种严重的脑血管疾病，死亡率和致残率极高。目前，针对脑出血的有效药物稀缺，迫切需要开发新的有效药物来治疗。神经元铁死亡和神经炎症是脑出血进展过程中重要的病理生理过程。然而，脑出血期间神经元铁死亡与神经炎症之间的潜在关系仍有待阐明。因此，阐明这种关系并进一步开发治疗药物可能为脑出血提供可行的治疗方法。在此，我们证实脑出血可诱导神经元铁死亡，这会导致促炎性小胶质细胞极化，并最终在脑出血后引发神经炎症进展。青龙衣纳米颗粒（QLY NP）治疗可抑制神经元铁死亡，从而抑制促炎性小胶质细胞极化，减少小鼠血肿体积，并最终在脑出血的情况下促进神经元存活并减轻神经炎症。同时，QLY NP治疗对小鼠的毒性极小。总体而言，我们表明QLY NPs可抑制神经元铁死亡，从而减轻神经炎症，并最终在脑出血模型中带来有前景的治疗效果。因此，随着进一步研究，QLY NPs可能是治疗脑出血的有效方法。
